Artifical Blood: How Close Are We?
By Janet Vasquez, published Oct 23, 2007
Published Content: 16 Total Views: 3,018 Favorited By: 0 CPs
American blood banks are experiencing critical shortages of lifesaving blood-especially during the summer months. It is reported that in the U.S. alone, someone needs a red blood transfusion every three seconds. One in three people will need a blood transfusion in their lifetime.
The success in finding a blood substitute would go a long way in relieving the blood shortage. The search for a viable blood substitute has just become more encouraging.
Although the last 35 years have seen previous efforts fail because of toxicity issues, one strategy to identify and nullify the source of toxicity seems to be promising. HemoBioTech, a Dallas-based pharmaceutical company, is developing a viable blood substitute, called HemoTech, that is expected to be compatible with all blood types and have a shelf life of 180-plus days, compared to 42 days for donated blood.
The blood substitute is composed of chemically modified bovine hemoglobin. In natural blood, hemoglobin binds with oxygen as the blood travels through the lungs and drops it off at the cells, throughout the body. HemoTech works the same way, by carrying oxygen in the blood to the cells, and it has an additional benefit of actually inducing red blood cell production.
Healing Blood
Researchers at Texas Tech University Health Sciences Center began developing HemoTech in 1985. The research and development effort was led by two of the world's foremost blood substitute authorities, Drs. Mario Feola and Jan Simoni.
In one limited clinical study, nine sickle cell anemia patients were infused with an amount of blood substitute representing 25 percent of the patients' blood volume. That limited clinical trial resulted in significant patient improvement and showed that a blood substitute can work as an effective oxygen carrier in humans without any toxic side effects.
Artifical Blood: How Close Are We?
Some scientists believe that a viable blood substitute would be a medical breakthrough that could potentially save millions of lives every year.
Credit: Fotolia
Copyright: Fotolia
You may also like...
- Artificial Blood Research and Ethics
- Malaria, Sickle-Cell Anemia, and Natural Selection
- Sickle Cell Blood Disorder: Improving Longevity with Preventative Health Care Options
- Acute Chest Syndrome & Organ Failure Syndrome: Blood Transfusion Cases of Sickle Cell
- What is Sickle Cell Anemia
- Sickle Cell Anemia
- Researchers Say They Were Able to Cure Sickle Cell Anemia in Mice
- Treating Sickle Cell Anemia
- Finding Information Online About Sickle Cell Anemia
- My Son was Born with Sickle Cell Disease
Takeaways
- Researchers at Texas Tech University Health Sciences Center began developing HemoTech in 1985.
- Hemotech is compatible with all blood types
- The blood substitute has a shelf life of 180-plus days
Did You Know?
Each year, the Red Cross collects approximately 6.5 million units of blood, from roughly 4.5 million volunteer blood donors.
Resources
Comments
Type in Your Comments Below - (1000 characters left)
Most Commented On


